

# Correspondence

## INSTRUCTIONS FOR LETTERS TO THE EDITOR

Editorial comment in the form of a Letter to the Editor is invited; however, it should not exceed 800 words, with a maximum of 10 references and no more than 2 figures (submitted as camera ready hard copy per Journal Guidelines) or tables and no subdivision for an Abstract, Methods, or Results. Letters should have no more than 3 authors. Full name(s) and address of the author(s) should accompany the letter as well as the telephone number, fax number, or E-mail address.

Contact: The Managing Editor, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto, ON CANADA M4W 3L4. Tel: 416-967-5155; Fax: 416-967-7556; E-mail: jrheum@jrheum.com Financial associations or other possible conflicts of interest should always be disclosed.

## Still a Blind Spot for Osteoporosis Prevention and Treatment for Rheumatoid Arthritis

To the Editor:

In the September issue of *The Journal*, Drs. Zochling and March commented<sup>1</sup> on our editorial<sup>2</sup> in which we noted the absence of recommendations for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis (RA).

They referred to the American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines update 2002<sup>3</sup>, which, they state, addressed the issue of osteoporosis prevention for patients with RA. However, these guidelines contain only the following sentence within the text of the article: "RA is associated with an increased risk of osteoporosis independently of glucocorticoid therapy." There is a recommendation for bone mineral densitometry as well as vitamin D and calcium supplement only for RA patients who are taking glucocorticosteroid. But these recently published guidelines, like the 2 we reviewed<sup>4,5</sup>, as well as the recent consensus statement on pharmacological management of early RA<sup>6</sup>, failed to deal with the need for osteoporosis prevention in RA patients in general. Only the recent article of Haugeberg, *et al*<sup>7</sup> also raised the question of identifying RA patients at high risk for osteoporosis, identifying 5 criteria: age, weight, inflammation, immobility, and ever-use of corticosteroids.

The role of corticosteroids in RA was the principal focus of Drs. Zochling and March, and this was well described in this Guidelines update<sup>3</sup>. However, every patient undergoing glucocorticoid treatment needs bone mineral densitometry evaluation and consideration of treatment for osteoporosis, as recently reiterated by Saag, *et al*<sup>8</sup>, so this is not specific to patients with RA.

This unfortunately reinforces our contention that the prevention and treatment of osteoporosis in patients with RA continues to be insufficiently addressed in published guidelines for management of RA. Our colleagues who work on the osteoporosis side are doing better — as evidenced by the Guidelines on Osteoporosis Management recently published by the Osteoporosis Society of Canada<sup>9</sup>, which list RA as a risk factor for the development of osteoporosis.

BRIGITTE M. JOLLES, MD, MSc, Hôpital Orthopédique de la Suisse Romande, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 4 Avenue Pierre Decker, 1005 Lausanne, Switzerland. (E-mail: Brigitte.Jolles@chuv.hospvd.ch); EARL R. BOGOCH, MD, MSc, FRCS, Department of Surgery, University of Toronto, Martin Family Centre for Arthritis Care, Mobility Program, St. Michael's Hospital, Suite 800, 55 Queen Street East, Toronto, Ontario M5C 1R6, Canada (E-mail: bogoch@sympatico.ca)

## REFERENCES

1. Zochling J, March L. First do no harm — a bone of contention in rheumatoid arthritis [editorial]. *J Rheumatol* 2002;29:1818-20.
2. Jolles BM, Bogoch ER. Current consensus recommendations for rheumatoid arthritis therapy: a blind spot for osteoporosis prevention and treatment [editorial]. *J Rheumatol* 2002;29:1814-7.
3. Anonymous. Guidelines for the management of rheumatoid arthritis: 2002 Update. *Arthritis Rheum* 2002;46:328-46.
4. Emery P. Overview of current therapies for rheumatoid arthritis. *J Rheumatol* 2001;28 Suppl 62:1-3.
5. Wolfe F, Cush JJ, O'Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. *J Rheumatol* 2001;28:1423-30.
6. Emery P. Is it time for a European consensus on the pharmacological management of early RA? *J Rheumatol* 2002;29 Suppl 66:1-2.
7. Haugeberg G, Orstavik RE, Uhlig T, Falch JA, Halse JI, Kvien TK. Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. *Ann Rheum Dis* 2002;61:1085-9.
8. Saag KG, Pisu M. Balancing bones and bucks among new glucocorticoid users [editorial]. *J Rheumatol* 2003;30:1-3.
9. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. *CMAJ* 2002;167:S1-34.

## Dr. Zochling and Dr. March reply

To the Editor:

Drs. Jolles and Bogoch<sup>1</sup> have highlighted an important shortcoming of current rheumatoid arthritis (RA) guidelines, in the lack of direction for prevention and management of associated osteoporosis. We agree wholeheartedly, and suggest it is perhaps a result more of the lack of good scientific evidence on which to base such guidelines than a lack of recognition. Little is known about the natural history of bone loss and associated fracture risk in steroid-naïve RA. Corticosteroid therapy is renowned for causing bone loss in other disease states, but in RA the association of osteoporosis and disease activity complicates the picture.

It may well be that with more aggressive use of disease modifying agents and biologic therapies, improved control of disease activity will bring with it an opportunity to more adequately assess the progression of osteoporosis in RA independent of corticosteroids in prospective studies, and to define the most appropriate management strategies.

Until that time, any guidelines must make it clear they are based on evidence that is incomplete. We agree that the management of any patients with RA should include assessment of the risk of osteoporosis, including underlying disease activity, demographics, and potential corticosteroid use.

JANE ZOCHLING, MBBS, FRACP, MMed (ClinEpi), Research Fellow in Rheumatology, Institute of Bone and Joint Research, Department of Rheumatology, Royal North Shore Hospital, Pacific Highway, St. Leonards, NSW, Australia 2065 (E-mail: jzochlin@med.usyd.edu.au); LYN MARCH, MBBS, MSc, PhD, FRACP, FAFPHM, Associate Professor of Medicine, Senior Staff Specialist in Rheumatology and Clinical

## REFERENCE

1. Jolles BM, Bogoch ER. Current consensus recommendations for rheumatoid arthritis therapy: a blind spot for osteoporosis prevention and treatment. *J Rheumatol* 2002; 29:1814-7.

## Fatigue and Psychological States and Traits in Systemic Lupus Erythematosus: Association or Causation?

To the Editor:

We read with interest the article by Omdal and colleagues, with results from a study of psychological characteristics of fatigued patients with systemic lupus erythematosus (SLE). Applying a cross-sectional design, they found that fatigue, as measured by the Fatigue Severity Score, was correlated with measures of depression, hysteria, anxiety, and social dysfunctioning<sup>1</sup>. The authors have previously reported a lack of association between fatigue and biological markers of disease activity in the same population<sup>2</sup>. They conclude that psychological factors like response and adaptation to a chronic disease appear to be the most important determinant of fatigue, and the high prevalence of fatigue is probably caused by personality traits common in patients with SLE.

The study seems nicely performed, and the applied statistical methods seem appropriate. The authors, however, seem to mistake correlation with causation.

The correlation between fatigue and symptoms of depression is based on the Beck Depression Inventory (BDI). Fatigue is one of the key symptoms of depression and fatigue/energy questions are therefore embedded in most diagnostic instruments. Consequently, a fatigued population will necessarily score higher on a depression scale, clinically depressed or not. It has been suggested that the only way to overcome this methodological problem is to discharge fatigue/energy items from the depression inventory<sup>3</sup>. The authors themselves deliver an argument for this point of view, since no correlation was found with the "depression" factor in the General Health Questionnaire (GHQ-30) and the Fatigue Severity Score. The GHQ-30, and consequently the depression factor derived from GHQ-30, does not include any fatigue/energy questions<sup>4</sup>.

The reported correlation between fatigue and hysteria is based on the Hysteria-axis in the Multiphasic Personality Inventory (MMPI). The MMPI claims to detect stable personality traits. However, as Creed and Ash point out, the MMPI includes several items that rheumatologists commonly attribute to disease rather than change in psychological status; for example, "I have few or no pain"<sup>5</sup>. With respect to fatigue, the instrument includes a significant number of fatigue/energy items (Table 1). Again, any fatigued population would score higher on this scale, disregarding present psychopathology or not. It has been suggested that the MMPI for this reason should not be used in patients with rheumatological diseases because "their elevated score on some dimensions, e.g., hypochondriasis, depression and hysteria, may reflect the disease rather than psychopathology"<sup>6</sup>.

Many aspects of the etiology and pathogenesis of SLE still remain to be solved, and no single valid biomarker for disease activity or organ involve-

Table 1. Examples of fatigue-related items in the "Hysteria-axis" from the MMPI. Numbers refer to item numbers in MMPI-2.

39	My sleep is fitful and disturbed (true)
175	I feel weak all over much of the time (true)
3	I wake up fresh and rested most mornings (false)
10	I am about as able to work as I ever was (false)

ment has been found. Gladman, *et al* compared disease activity in SLE patients with 5 health status instruments: the Health Assessment Questionnaire, Functional Ability Index, the Fatigue Severity Scale, the Disability Days Measure, the Centre for Epidemiological Studies-Depression Scale, and the Medical Outcomes Study Short Form Health Survey (SF-20) during their clinic visit. Disease activity was measured using the SLE Disease Activity Index (SLEDAI). Inter-instrument correlation analysis revealed that components of the SF-20 correlated significantly with each of the other instruments used, while there was no correlation between any of the health status instruments used and the SLEDAI. They suggested that health status assessment as measured by the SF-20 is a valid independent outcome measure in patients with SLE. It could also be argued that the lack of correlation between self-reported health and objective measures of disease activity disclose the inability of existing clinical markers to detect disease burden as it is perceived by the patient.

We agree with the authors that fatigue in chronic disease is a complex phenomenon, but with the lack of valid biomarkers it is important to ask if cross-sectional studies add to our understanding of causal and modifying factors for the development and course of fatigue in SLE and other chronic diseases.

NIELS HENRIK HJOLLUND, MD, PhD; OLE NØRBY HANSEN, MSc, PhD, Department of Occupational Medicine, Herning Central Hospital, Gl. Landevj 61, DK-7400 Herning, Denmark. E-mail: hhjol@akh.aaa.dk

## REFERENCES

1. Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI. Fatigue in patients with systemic lupus erythematosus: the psychosocial aspects. *J Rheumatol* 2003;30:283-7.
2. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. *J Rheumatol* 2002;29:482-6.
3. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? *Support Care Cancer* 1998;6:101-8.
4. Huppert FA, Walters DE, Day NE, Elliott BJ. The factor structure of the General Health Questionnaire (GHQ-30). A reliability study on 6317 community residents. *Br J Psychiatry* 1989;155:178-85.
5. Creed FH, Ash G. Depression in rheumatoid arthritis: aetiology and treatment. *Int Rev Psychiatry* 1992;4:23-34.
6. Bowling A. Measuring disease: a review of disease-specific quality of life measurement scales. 2nd ed. Buckingham, UK: Open University Press; 2001.
7. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus. *Lupus* 1996;5:190-5.

## Dr. Omdal, *et al* reply

To the Editor:

We thank Drs. Hjollund and Hansen for their interest in our report. Their letter contains important views on the topic of fatigue in autoimmune diseases, and is written with insight concerning fatigue and psychology. With a few exceptions, we have no problem agreeing with most of their arguments, but would like to comment on them.

Considering mistaking correlation with causation, we cannot quite understand that the message from our study should be interpreted as that. It is clear from the text that this is a cross-sectional study, and it should also be emphasized that we use the word *association* throughout<sup>1</sup>. This word does not imply any specific causation, only that some variables covariate: *correlation* — as Hjollund and Hansen call it. Having said that, the procedure for unveiling the mechanisms of fatigue in these diseases would include prospective studies, intervention studies, and search for biomarkers of the fatigue phenomenon, as emphasized by Hjollund and Hansen.

Their comments regarding fatigue and depression are important. Mutually related factors may cause “circular argumentations” leading to conclusions of associations that do not exist. This is a well known phenomenon, but sometimes hard to exclude since the associations may be unknown, or the researcher unaware of relationships among the variables.

Hjollund and Hansen argue that the Beck Depression Inventory (BDI) contains several items related to fatigue, while the General Health Questionnaire (GHQ-30) does not. They also argue that we find no association between fatigue and the depression factor (Factor C) in the GHQ-30, while such a relationship is evident in the BDI.

Factor C in the GHQ-30 is significantly associated to fatigue ( $R^2 = 0.24$ ,  $p = 0.0001$ ) by simple regression analysis. It is only in a stepwise regression model that Factor C does not significantly contribute to fatigue. This does not imply lack of association between fatigue and the items of Factor C, but indicates that Factor C does not independently contribute enough to the association with fatigue to be maintained in a multivariate model<sup>1</sup>. To some extent, we can therefore agree with Hjollund and Hansen’s argument.

Further, the BDI is a 21 item questionnaire pertaining to cognitive/emotional and somatic manifestations of depression. The first 13 items assess cognitive/affective symptoms of depression; the final 8 items evaluate somatic phenomena of depression. Our study also showed an association between the cognitive/affective items of the BDI and fatigue, indicating that it is not the fatigue/energy items of the BDI that are the most important aspects of depression for patients with SLE.

It has been suggested<sup>2</sup> that the Multiphasic Personality Inventory (MMPI) should not be used in patients with rheumatological diseases. This may be true for arthritis and other joint-related diseases, but our patients with SLE are characterized by few or no joint manifestations and have features more related to systemic disease. In this context, we see no reason for not applying the MMPI instrument in SLE.

Also, the Hysteria-axis in the MMPI-2 includes 60 items. Almost all items on Scale 3 are scores on other clinical scales; only 10 items are unique to Scale 3. Some of the items deal with a general denial of physical health and some specific somatic complaints. Another group of items involves a rather general denial of psychological or emotional problems and of discomfort in social situations. Although these 2 clusters of items are reasonably independent in normal subjects, persons displaying hysterical defenses seem to score high on both clusters<sup>3,4</sup>. Indeed, it is not possible to obtain a T score above 65 on Scale 3 without endorsing both kinds of items. Patients with bona fide medical problems lacking any evident psychological component tend to obtain T scores of about 55–60 on this scale<sup>3,4</sup>.

However, Hjollund and Hansen’s concern about the BDI and MMPI-2 versus fatigue reflects to a considerable extent the problem of mutually related variables — a matter in which we fully agree.

Finally, Hjollund and Hansen refer to the study by Gladman, *et al*<sup>5</sup> where 5 health status instruments in SLE were compared by correlation analysis, and suggest that health status assessment as measured by the Medical Outcomes Study Short Form (SF-20) is a valid independent outcome measure in SLE. Applying correlation statistics for comparing different instruments (measuring agreement between 2 methods) is in our opinion questionable. A more adequate approach is estimation of limits of agreement<sup>6</sup>. The results of such a comparison between the health instruments are unknown, as far as we know. Whether the SF-20 is superior in evaluating fatigue in patients with SLE therefore remains to be seen.

ROALD OMDAL, MD, PhD, Clinical Immunology Unit, Rogaland Central Hospital, N-4068 Stavanger, Norway; KNUF WATERLOO, PsyD, Department of Neurology; WENCHE KOLDINGSNES, MD, Department of Rheumatology, University Hospital of North Norway; GUNNAR HUSBY, MD, PhD, Department of Rheumatology, National Hospital, Oslo; SVEIN MELLGREN, MD, PhD, Department of Neurology, University Hospital of North Norway; BJØRN STRAUME, MD, Institute of Community Medicine, University of Tromsø.  
E-mail: romdal@online.no

## REFERENCES

1. Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI. Fatigue in patients with systemic lupus erythematosus: The psychosocial aspects. *J Rheumatol* 2003;30:283-7.
2. Bowling A. Measuring disease: a review of disease-specific quality of life measurement scales. 2nd ed. Buckingham, UK: Open University Press; 2001.
3. Graham JR. MMPI-2. Assessing personality and psychopathology. New York: Oxford University Press; 1990.
4. Greene RL. The MMPI-2/MMPI: An interpretive manual. Boston: Allyn and Bacon; 1991.
5. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus. *Lupus* 1996;5:190-5.
6. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;1:307-10.

---

## Hands-on Treatment in Rheumatology

*To the Editor:*

The editorial by Fitzcharles<sup>1</sup> regarding “hands-on” treatments in rheumatology is timely and balanced. She noted the seemingly low frequency of side effects of spinal manipulation and wonders whether this is due to underreporting or the rarity of complications.

We recently surveyed all UK neurologists asking them to note all neurological adverse effects of spinal manipulation seen within the last year<sup>2</sup>. Our response rate was 74% and 35 cases of often serious complications were reported. None of these had been published in the medical literature. It follows that, in our case, underreporting was exactly 100%. I therefore agree with Fitzcharles that (chiropractic) manipulation (particularly of the upper spine) is associated with serious complications of unknown frequency. The incidence rates reported by chiropractors are pure speculation and, in view of huge underreporting, even nonsensical. The inescapable conclusion is that we need conclusive incidence figures. Until they are available, caution seems well advised.

EDZARD ERNST, MD, PhD, FRCP, FRCPEd, Director, Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter, EX2 4NT, UK.  
E-mail: Edzard.Ernst@pms.ac.uk

## REFERENCES

1. Fitzcharles M-A. Is it time for rheumatologists to rethink the use of manual therapies? [editorial]. *J Rheumatol* 2002;29:1117-20.
2. Stevinson C, Honan W, Cooke B, Ernst E. Neurological complications of cervical spine manipulation. *J Roy Soc Med* 2001;94:107-10.

## Dr. Fitzcharles replies

*To the Editor:*

The comments of Prof. Ernst are appreciated. Once again caution in the use of manipulation therapies is advocated. Good medical practice requires that a physician should be fully aware of risks associated with a treatment before prescription. We do not currently have accurate information regarding risks related to “hands-on” or manipulation therapies. Prof. Ernst and colleagues have recently demonstrated the high rate of underreporting of neurological events following spinal manipulation<sup>1</sup>. This survey of physician habits, which is likely reflective of usual practice, raises further concerns about the true frequency of side effects due to any treatment without a formal monitoring procedure. The literature abounds with anecdote, case reports, and polls from physicians, none sufficient to give reliable estimates of risk.



Attempts at systematic review or metaanalysis of manipulation therapies concede that the quality of clinical trials, mostly examining efficacy, but also reporting on risks, is generally poor. Risk of harm is clearly of importance to prescribers. Although a recent metaanalysis reported that spinal manipulation was no better than other commonly used treatments for low back pain, advantages or risks associated with various treatments were not addressed<sup>2</sup>. In a population-based study examining the relationship of stroke and chiropractic manipulation, the rates for chiropractic visits were similar in the preceding year for both patients and the population controls. However, differences only emerged when the groups were divided according to age of 45 years, with younger stroke patients reporting more chiropractic visits<sup>3</sup>.

Once again there is a strong call for rigorous scientific evidence before these treatments can be universally endorsed.

MARY-ANN FITZCHARLES, MB, ChB, MRCPUK, FRCPC, Associate Professor of Medicine, Division of Rheumatology, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada

#### REFERENCES

1. Stevinson C, Honan W, Cooke B, Ernst E. Neurological complications of cervical spine manipulation. *J Roy Soc Med* 2001;94:107-10.
2. Assendelft WJJ, Morton SC, Yu EI, Suttrop MJ, Shekelle PG. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies. *Ann Intern Med* 2003;138:871-81.
3. Rothwell DM, Bondy SJ, Williams JI. Chiropractic manipulation and stroke. A population-based case-control study. *Stroke* 2001;32:1054-9.

---

### Another Look At Wegener's Granulomatosis-Associated Pachymeningitis

To the Editor:

Fam, *et al* recently described an unusual manifestation of Wegener's granulomatosis (WG) with cranial pachymeningitis and reviewed the literature<sup>1</sup>. We read their report with great interest, as we had reported 3 cases of severe central nervous system (CNS) manifestations in generalized WG and reviewed the literature ourselves<sup>2</sup>. In contrast to Fam, *et al*, we found 18 patients with meningeal involvement, all proven by biopsy. Yet Fam, *et al* did not mention that 9 out of 20 patients (45%) with meningeal involvement and known antinuclear cytoplasmic antibodies (ANCA) results were found to be ANCA negative. Although the sensitivity for cANCA/PR3-ANCA approaches almost 100% in acute generalized WG, there are published reports of about 12 patients with generalized WG and negative ANCA in the English literature. On top of that, out of these 12 patients with ANCA-negative WG, 83% (10 patients) had cerebral and/or meningeal involvement.

Fam, *et al* did not point out that according to the literature, 83% of patients with WG and cerebral involvement are persistently ANCA-negative versus just 10% with "classic" WG, as shown in larger cohorts. In addition to broader awareness of this data, further studies and other initiatives are needed to distinguish this subset of ANCA-negative WG with predominant CNS involvement from others.

PEER MALTE ARIES, MD; EVA REINHOLD-KELLER, MD; WILHELM LUDWIG GROSS, MD, Universitätsklinikum Schleswig Holstein, Poliklinik für Rheumatologie, Rheumaklinik Bad Bramstedt, Oskar Alexander Strasse 26, 24576 Bad Bramstedt, Germany. E-mail: aries@rheuma-zentrum.de

#### REFERENCES

1. Fam AG, Lavine E, Lee L, Perez-Ordóñez B, Goyal M. Cranial pachymeningitis: An unusual manifestation of Wegener's granulomatosis. *J Rheumatol* 2003;30:2070-4.
2. Reinhold-Keller E, de Groot K, Holl-Ulrich K, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies. A report of 3 cases and a review of the literature. *Clin Exp Rheumatol* 2001;19:541-9.

#### Dr. Fam replies

To the Editor:

We appreciate the comments by Aries, *et al* and their interest in our study<sup>1</sup>. In its classic generalized form, WG chiefly affects the upper and lower respiratory tracts and kidneys. In the limited or partial form, the pathological findings of necrotizing granulomatous vasculitis are similar but the upper respiratory tract, orbit, or lung are primarily affected, in the absence of renal disease<sup>1</sup>.

Measurement of serum cytoplasmic antineutrophil cytoplasmic antibody (cANCA/PR3-ANCA) is highly specific for WG, with a sensitivity greater than 90% for active generalized WG, but only 67% for those with active limited disease. Thus, ANCA is absent in one-third of patients with limited WG<sup>1-3</sup>.

Reinhold-Keller, *et al*<sup>4</sup> described 3 patients with active, ANCA-negative WG and severe neurologic manifestations: leptomeningitis in 2 and cerebrospinal lesions in one. However, the absence of renal disease in all 3 patients raises some question whether these subjects had limited rather than generalized WG<sup>4</sup>. Review of reported patients with WG-associated meningeal disease revealed that 45% of cases were ANCA-negative<sup>4</sup>.

Our study, which focused on meningeal inflammation in WG, showed that most reported cases occurred early (within 6 months of onset) in the course of active, limited WG, and that about one-third of patients were ANCA-negative<sup>1</sup>. In accord with other studies, our patient developed pachymeningitis in the setting of active, limited WG. ANCA was repeatedly negative initially, but she subsequently developed pANCA/myeloperoxidase (MPO) antibodies, which disappeared following successful immunosuppressive therapy for WG<sup>1</sup>. A possible association between limited WG, pANCA/MPO antibodies, and pachymeningitis has recently been described by Japanese investigators<sup>5</sup>.

Thus an association between active limited WG and pachymeningitis with variable ANCA results, but a trend toward cANCA negativity and pANCA positivity, is proposed but remains unproven. To confirm these clinical observations, further case-control studies of this rare manifestation of WG, and new insights into the pathogenetic roles of cANCA and pANCA antibodies, are required. Greater awareness, early recognition, and timely therapy of WG-associated pachymeningitis are important to minimize permanent neurologic damage.

ADEL G. FAM, MD, FRCPC, Division of Rheumatology, Sunnybrook and Women's Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Room M1-402, Toronto, Ontario M4N 3M5, Canada. E-mail: Adel.Fam@Sunnybrook.on.ca

#### REFERENCES

1. Fam AG, Lavine E, Lee L, Perez-Ordóñez B, Goyal M. Cranial pachymeningitis: an unusual manifestation of Wegener's granulomatosis. *J Rheumatol* 2003;30:2070-4.
2. Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (C-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. *Ann Intern Med* 1995;123:925-32.
3. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. *Arthritis Rheum* 1998;41:1521-37.

- Reinhold-Keller E, de Groot K, Holl-Ulrich K, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies. A report of 3 cases and a review of the literature. *Clin Exp Rheumatol* 2001;19:541-9.
- Nagashima T, Maguchi S, Terayama Y, et al. P-ANCA-positive Wegener's granulomatosis presenting with hypertrophic pachymeningitis and multiple cranial neuropathies: case report and review of literature. *Neuropathology* 2000;20:23-30.

### A Randomized, Double Blind, Placebo Controlled Trial of a Topical Cream Containing Glucosamine Sulfate, Chondroitin Sulfate, and Camphor for Osteoarthritis of the Knee

*To the Editor:*

I'm confused how the fatal methodological flaws in this study<sup>1</sup> were not uncovered in editorial review, and that this study was allowed to be published.

The most glaring problem, the "treatment" group used a topical product that contained a known active ingredient, camphor, while this was absent from the placebo group. This does not support the author's conclusion that "Topical application of glucosamine and chondroitin sulfate is effective in relieving the pain from OA of the knee." The proper conclusion should be that camphor was effective in short term pain relief, or better yet, no conclusion could be drawn on glucosamine and chondroitin because the "active" group contained 3 variables compared to the placebo-treated group.

This is not the only flaw. Subjects in the study were apparently allowed to apply treatment or placebo "ad lib" and were not required to "dab" the product, as is often the standard in study of topical agents. The act of rubbing the joint alone may help reduce symptoms. The camphor-containing "active" product may have been used more often by the subjects, further biasing the results. Finally, camphor has a burning sensation not found with peppermint oil. The absence of camphor in the placebo group could have unblinded the trial.

There is no evidence that glucosamine and chondroitin are absorbed in the skin, and certainly none that shows any significant levels are achieved by topical application. Further, the active product contained only a small quantity of glucosamine and chondroitin. We know from oral studies that a minimum threshold concentration is required for effect.

JASON THEODOSAKIS, MD, MS, MPH, FACPM, Steering Oversight Committee Member, NIH Trial on Glucosamine and Chondroitin, Assistant Professor, University of Arizona, Tucson, Arizona, USA.

Dr. Theodosakis's activities and relationships with regards to companies and products related to the treatment of osteoarthritis are the following: Celebrex, Pfizer Pharmaceuticals (speaker); Hyalgan, Sanofi-Synthelabo (consultant); glucosamine/chondroitin and Avocado-Soy Unsaponifiables, NBTY (consultant); SAmE, glucosamine/chondroitin, Pharmavite (consultant); anti-inflammatory Philodendron extract, Next Pharmaceutical (research advisor).

#### REFERENCE

- Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. *J Rheumatol* 2003;30:523-8.

*To the Editor:*

I have some major concerns regarding Cohen, *et al's* article on the benefits of topical glucosamine sulfate<sup>1</sup>. How did this article slip through your peer review process with the words "double blind" in the title?

The "active" cream contains not only glucosamine and chondroitin sulfate, but also peppermint oil and camphor. The placebo was a "simple cosmetic cream that used conventional skin emollients, petrolatum and mineral oil." Unless the experimental subjects were anosmic, they would be aware which cream they were using; indeed, if they applied it shortly before being assessed, the experimenters would also be unblinded. At best this study was single blind; at worst it is completely unblinded by the failure to match the odor of the placebo to that of the "active" cream.

MATTHEW L. GROVE, BSc, MRCP, Consultant Rheumatologist, North Tyneside Hospital, North Shields, Tyne and Wear, NE29 8NH, United Kingdom.

#### REFERENCE

- Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. *J Rheumatol* 2003;30:523-8.

#### Dr. Cohen replies

*To the Editor:*

The letters from Drs. Theodosakis and Grove raise a number of issues concerning our study<sup>1</sup>, including issues to do with the study blinding as well as the administration of the intervention and the conclusions drawn regarding the contribution of glucosamine and chondroitin to the therapeutic results.

Regarding the study being de-blinded, this is certainly not the case. The active and placebo creams both contained peppermint oil, which effectively matched them with regard to odor. Further, while there may have been a slight difference between the creams due to the presence of camphor in the active preparation, both the subjects and investigators were naive to any difference, and the subjects did not bring their creams to clinic visits and did not meet in the waiting room, thereby ensuring that no contamination occurred. Further, blinding was formally checked with subjects being asked at each visit which group they thought they had been allocated to. The data from these assessments indicate that blinding was maintained (see Table 1).

It is unlikely that the method of application influenced the results of this study. Having the subjects rub rather than dab the cream may have contributed to the observed pain reduction seen in the placebo group; however, this effect would not have led to the observed difference between the groups. Over the course of the trial the active group used a total of 5.5 tubes, while the placebo group used 5.7 tubes.

Finally, the contribution of glucosamine and chondroitin to the observed pain reduction in the active group is open to speculation and cannot be determined by the current study. Unfortunately, the doses of these ingredients were overstated in the original article by a factor of 10. Thus the active intervention actually contained glucosamine sulfate (3.0 mg/g), chondroitin sulfate (7.2 mg/g), and shark cartilage (14 mg/g), of which 10–30% is chondroitin sulfate, along with camphor (32 mg/g) and peppermint oil (9 mg/g).

The effective dose of glucosamine and chondroitin delivered to a painful joint is uncertain. Based on animal studies it is evident that even though there is active uptake of glucosamine by articular cartilage, only around 0.4% of an administered oral dose is delivered to cartilage tissue<sup>2</sup>. Extrapolating this to humans would equate to approximately 6 mg of a 1500 mg oral dose. This is in the range delivered by topical administration in our study, and the observed gradual and progressive improvement is consistent with studies using oral administration of these agents. Thus while the study title refers to glucosamine, chondroitin, and camphor, the exact mechanisms of action of the cream used in our study are yet to be determined, and it is premature to discount the therapeutic effect of topical glu-

Table 1. Treatment allocation versus subjects' assessment of allocation.

Actual Group Allocation	Subject's Assessment of Allocation at 4 Weeks	Subject's Assessment of Allocation at 8 Weeks
Active group	14 Active 10 Placebo 8 Don't know	17 Active 13 Placebo 1 Don't know
Placebo Group	9 Active 14 Placebo 6 Don't know	12 Active 15 Placebo 2 Don't know

cosamine and chondroitin. The study certainly does provide evidence that the active cream containing camphor, glucosamine, and chondroitin is safe and effective in reducing the pain from osteoarthritis of the knee. The relative contribution of these ingredients is now the subject of ongoing research.

MARC COHEN, MD, Head, Department of Complementary Medicine, RMIT University, PO Box 71, Bundoora, Victoria 3083, Australia.  
E-mail: marc.cohen@rmit.edu.au

#### REFERENCES

1. Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. *J Rheumatol* 2003;30:523-8.
2. Setnikar I, Giacchetti C, Zanolio G. Pharmacokinetics of glucosamine in the dog and in man. *Arzneimittelforschung* 1986;36:729-35.



#### Fibromyalgia — Real or Imagined?

To the Editor:

It seems that editorials in medical journals are designed principally to identify problems rather than find solutions. With this in mind, I am intrigued by the editorial blitzkrieg you have unleashed against that common, unfortunate malady we call fibromyalgia (FM). It would appear that your purpose is to ban FM once and for all from rheumatology practices, research endeavors, and training programs and to exile these ladies to a medical limbo and into the clutches of con men, charlatans, and the expert advice of the Internet. Just one year ago, one of our leaders was widely quoted<sup>1</sup> that rheumatologists were too busy and too important to waste their time with patients with FM. I am distressed at the disinterest and lack of compassion of my colleagues. Dr. Ehrlich states that tuberculosis is always tuberculosis<sup>2</sup>, but I do remember historic terms such as consumption and the miasmas and curses and other causes which were entertained. Fortunately, Dr. Ehrlich's namesake, a century ago, did not dismiss syphilis, tuberculosis, and other infectious diseases and abandon his pioneering studies, which

have led to modern immunology<sup>3</sup>. I also believe that it is safe to assume that none of the wives of your editorial contributors have symptoms we associate with FM or other imaginary illnesses.

I agree with Dr. Wolfe's opinion about the inappropriate use of American College of Rheumatology (ACR) criteria in the diagnosis of FM<sup>4</sup>, but he is the one who devised the criteria, published the information, and has since been widely quoted. The problem is that the ACR has a long history of describing diagnostic criteria for their various diseases of interest which have been constructed after many committee meetings. Such criteria and medical algorithms are sloppy methods to use in the practice of sound medicine and merely encourage the uninformed to render diagnoses which he is not competent to make. They do not serve any purpose other than in research and should otherwise be abandoned.

It may be helpful to understand how these criteria came about. Almost 50 years ago, I directed the Streptococcal Disease Laboratory at Western Reserve University, a group of investigators who were given the Lasker Award for studies in strep infections and rheumatic fever. One of my consultants was Dr. T. Duckett Jones, who headed the House of the Good Samaritan in Boston and was a member of the Streptococcal Disease Commission. Dr. Jones undoubtedly had seen more patients with rheumatic fever than anyone before or since. He was also acutely aware of the problems in the diagnosis of rheumatic fever, particularly studies in prevention and therapy such as we were then conducting (I hate to think what he would do with the current problems with Lyme disease). So that we were all on the same wavelength, he devised the widely quoted Jones Criteria<sup>5</sup>, but its sole purpose was for epidemiologic and clinical research and not to help a physician in individual patient care. Those of us who knew Duckett Jones will confirm this. The ACR over the past few decades has seen fit to copy Dr. Jones's effort in composing such criteria for many of the illnesses seen by rheumatologists, but these have been distributed to help the non-rheumatologist physician rather than as a research tool. Dr. Wolfe, his colleagues, and their predecessors have produced a litany of such shortcut diagnostic aids to enable the non-rheumatologists to arrive at a correct conclusion. But as Dr. Wolfe states, there is considerable overlap between the findings in FM and rheumatoid arthritis and although not mentioned, probably all forms of polyarthritis and perhaps other illnesses. The same is probably true of all diagnostic criteria for other illnesses which have been devised. In brief, Dr. Wolfe implies that such criteria are near-worthless and I would not disagree.

As a practicing rheumatologist, I must agree with much of what Drs. Ehrlich and Hadler state<sup>2,6</sup>. I do not have the foggiest idea what FM and chronic fatigue syndrome are, and the diagnosis is essentially made on a basis of the history and an absence of abnormal physical findings and laboratory tests. In my practice, most have had the diagnosis of FM made prior to my examination, by another physician, a relative or friends, or by exploring the Internet. At best, the diagnosis is correct in perhaps half of them. Without a specific physical or laboratory finding and with no knowledge of its cause or pathophysiology, I do not know how to explain this condition to the patient. I can only paraphrase Justice Potter Stewart, who, in describing pornography, said he doesn't know how to define it but he knows it when he sees it. In contrast to your experts, I find it difficult to believe that this is an iatrogenic disease. We saw such patients when I was a house-offi-

cer and subsequently labeled them as having fibrositis, a term which was hardly descriptive. And then the label was changed to FM, which is as specific as telling someone that they have a headache or a pain. Does it matter what we use as a term so long as we all understand what we are saying?

As I stated, editorial writers are great at defining problems, but your writers have failed to provide any solution other than to abandon these people and tell them to get out of our back yard. Whether we like it or not, the patient with FM is sick or believes that she is ill, and is able to function only on a reduced level. She is not liked by any male with whom she has close contact, whether it is her husband or her physician. She cries out for help but rarely receives it. She does not respond to drugs, is at risk of becoming habituated to analgesics, and is shunted between physicians and support groups, and quacks. As a rheumatologist, I would prefer to spend my time on other diseases, yet I would feel ashamed to neglect such patients or to refer them to whoever will get them out of my hair. At present, we are exploring other alternatives, which are thus far successful and which allow us to show the compassion these people deserve.

Finally, I need to admonish Dr. Gordon as the editor<sup>7</sup>. Americans have recently criticized our Canadian friends are being too liberal, politically correct, and too willing to accept social change. Knowing that men invariably dislike ladies with FM, it would have been more fair if you had had at least one female physician to join this group of male chauvinists. I believe that there would have been a more valid conclusion.

ALTON MORRIS, MD. Kingsport, Tennessee 37660, USA.

## REFERENCES

1. Wolfe F. Stop using the American College of Rheumatology criteria in the clinic [editorial]. *J Rheumatol* 2003;30:1671-2.
2. Ehrlich P, Hata S. Die experimentelle Chemotherapie der Spirillose. Berlin: Springer: 1910.
3. Ehrlich G. Pain is real. Fibromyalgia isn't [editorial]. *J Rheumatol* 2003;30:666-7.
4. Blann EF, Jones TD. The natural history of rheumatic fever: a 20 year perspective. *Ann Intern Med* 1952;37:1006-26. No abstract available.
5. Jones TD. The diagnosis of rheumatic fever. *JAMA* 1944;126:481-4.
6. Hadler NM. Fibromyalgia" and the medicalization of misery. *J Rheumatol* 2003;30:1668-70.
7. Gordon DA. Fibromyalgia. Real or imagined? [comment] *J Rheumatol* 2003;30:1665.

---

## Fibromyalgia. Reflections About Empirical Science and Faith

To the Editor:

This essay refers to the editorials by Gordon, Ehrlich, Hadler and Wolfe, published in the August 2003 issue of *The Journal*.

As medicine, rheumatology is an empirical science. In science, empiricism must be understood according to the ideas of the philosophers, like Hume and Berkeley<sup>1,2</sup>, who concluded that knowledge could only be acquired through sensory experience. In other words, the object of knowledge must be perceptible through one's senses.

When a scientist is looking for T CD4 lymphocytes in a human tissue, he or she is looking for empirical evidence. To achieve this, he or she works with a visible and tactile piece of tissue; stains it with visible, tactile, and smelly chemical substances, and gets something that can be visible with a microscope and that can be photographed. This is the empirical part of scientific work and the facts that are produced in it are empirical facts and empirical knowledge. They are visible, tactile, perceptible, and real.

However, when T CD4 lymphocytes are detected in a human tissue, what does this mean? To answer this, we need a different kind of knowl-

edge, an abstract knowledge. This is a "theoretical" knowledge and it is expressed with words. It can be based on empirical facts or faith.

When a patient has clinical manifestations of tuberculosis, like cough and sputum, fever, weight loss, and radiographically visible pulmonary lesions, the person really only knows that he or she has tuberculosis after a sequence of empirical facts. First, a laboratory test of tissue or secretion from that person has to show a structure, conventionally named *Mycobacterium tuberculosis*, which is visible by staining methods. Second, the result of the laboratory test is written on paper. Finally, a physician reads the result and translates into one word: tuberculosis.

One who gets *M. tuberculosis*, gets tuberculosis. This is a form of circular reasoning, which is scientifically acceptable because it is the presence of the bacillus (empirical fact) that defines the disease (theoretical knowledge). The same is true for cancer, of which the empirical basis is the malignant cell.

The development of criteria for fibromyalgia (FM)<sup>3</sup> classification was an attempt to give empirical support to a common situation in medical practice. A patient who complains of body pain over a long period of time represents this situation. When the complaint persists longer than 3 months and is diffuse, it is conventionally named widespread chronic pain.

With lack of empirical and specific evidence to define that clinical situation, the committee takes 2 additional items of evidence, which are the complaint of widespread chronic pain and the finding of tender points in a physical examination. I say "the complaint of widespread chronic pain" and not "widespread chronic pain" because "the complaint" is the only empirical form describing the phenomenon. When one says "widespread chronic pain," one is accepting the pain as being real, but that is an act of faith and causes judicial consequences.

The idea behind the development of the criteria attempts to define the word fibromyalgia as being the empirical evidence of someone complaining of widespread chronic pain and the finding of 11 or more tender points in a physical examination. The reasoning used is the passage of empirical evidence (complaint of widespread chronic pain and tender points) to a verbal significance (fibromyalgia). A mental process known as induction leads to this. Personally, I call it an inductive jump. The jump is from empirical facts to words. Induction is a process of thought where an act of faith turns empirical evidence into words, words into meanings, meanings into feelings, and feelings into realities. These realities reinforce the initial faith.

When someone jumps from a malignant cell to cancer or from *M. tuberculosis* to tuberculosis, those acts are accepted as scientific truth because there is no evidence showing there is tuberculosis without *M. tuberculosis* and cancer without a malignant cell. The association of these words is specific and complete. Even if in these cases there are inductive jumps from one word to another, they represent the same reality, in spite of using "malignant cell" for the isolated cell and "cancer" for the clinical expression of the disease; we are saying in an empirical way, malignant cell is cancer and cancer is a malignant cell. This "scientific tautology" is the basis of the meaning of words in science.

But this is not true for FM. Tender points are not specific for the complaint of widespread chronic pain, and the complaint of widespread chronic pain is not specific for FM, so the combination of tender points and the complaint of widespread chronic pain is not sufficient to construct a scientific tautology with the word fibromyalgia. The result is a concept that is not empirical, that is not verifiable. But it is useful.

It is useful because the construct has initiated scientific efforts to prove its veracity or deny its existence. These works have produced meaningful scientific knowledge of anatomical and biochemical phenomena involved in perception and modulation of pain. It is useful because it explains to patients that pain does not mean lesion or deformity, does not mean arthritis or cancer, does not mean disability or incapacity. And the prognosis of someone complaining of widespread chronic pain is not hopeless. There are patients that even complain of widespread chronic pain for a long time, who stop complaining after some time. If those patients had pain and the pain disappeared, it is a conclusion that current medicine cannot explain; there is no empirical evidence to do so. But if there are patients that com-



plain of widespread chronic pain for some time and at the same time have sleep disturbance, fatigue, and tender points, and then stop complaining and these manifestations disappear, we can say that there is hope for someone complaining of widespread chronic pain.

However, while the construct is useful in some aspects, it has failed in others because it is not empirical. Because FM is not verifiable, it cannot be denied, and this is more important than proving its existence. Nobody will go to court to request compensation for cancer without showing the malignant cell that defines the disease. Without the empirical proof, a claim for cancer cannot be defensible. But someone with bad intentions can claim compensation for FM because this complaint cannot be overturned by present-day knowledge. Astute lawyers certainly have perceived that, and the scientifically useful construct has been abused in legal proceedings, taking advantage of the law's inexactness and subjective determinations of incapacity and compensation<sup>4</sup>.

Physicians who have testified that patients complaining of widespread chronic pain really felt the pain, were moved by faith in words, but not by empirical evidence to support the scientific statement. Yet giving testimony, the physician is called to answer empirically, perhaps as follows:

Does the patient complain about widespread chronic pain?

"Yes."

Does the patient feel the pain?

"I can't affirm that."

Does the patient have fibromyalgia?

"No one can have fibromyalgia. Fibromyalgia is just a word we use to represent the situation of someone complaining about widespread chronic pain, fatigue, and sleep disturbance who has tender points on physical examination. It is not a disease, it's a description."

That's the difference between scientific tautology and pleonasm.

LUIZ CLAUDIO da SILVA, MD, Rheumatologist, Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil.  
E-mail: lclaudiosilva@terra.com.br

#### REFERENCES

1. Hume D. In: Norton DF, Norton MJ, editors. A treatise of human nature: being an attempt to introduce the experimental method of reasoning into moral subjects. (Oxford Philosophical Texts). Oxford: Oxford University Press; 2000.
2. Berkeley G. In: Dancy J, editor. A treatise concerning the principles of human knowledge (Oxford Philosophical Texts). Oxford: Oxford University Press; 1998.
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum* 1990;33:160-72.
4. Wolfe F. The fibromyalgia problem [editorial]. *J Rheumatol* 1997;4:1247-9.

### Systolic Blood Pressure in Patients with Osteoarthritis and Rheumatoid Arthritis

To the Editor:

The recent article by Singh, *et al*<sup>1</sup> raises an increasingly important issue: with the advent of cyclooxygenase-2 (COX-2) inhibitors, doctors seem to have forgotten that nonsteroidal antiinflammatory drugs (NSAID) have important adverse effects. The effects on blood pressure are often more severe than the few mm Hg that they highlight. I frequently see patients whose blood pressure has been significantly aggravated by NSAID, including COX-2 inhibitors. However, like many, they seem to have forgotten that not all NSAID are created equal with respect to effects on blood pressure.

We showed<sup>2</sup> that in contrast to other NSAID, sulindac does not raise blood pressure, and that this difference was due to sparing of renomedullary vasodilator prostaglandins. I have suspected for some time that the (to me) surprising neglect of our report may have been related to the apparent small size of the sample (30 patients). However, because it was a 4-way complete-crossover design, the study had a greater power than would a parallel-group study in 120 patients. It was also more relevant to the clinical situation than some other negative studies at the time done in healthy volunteers, in that we studied patients with hypertension, stabilized on beta-blocker and diuretic.

As Santayana pointed out, those who forget history are doomed to repeat the mistakes of the past. Patients with hypertension, congestive heart failure, or other conditions aggravated by retention of salt and water will do better taking sulindac than other NSAID.

J. DAVID SPENCE, MD, Stroke Prevention and Atherosclerosis Research Centre, 1400 Western Road, London, Ontario N6G 2V2, Canada.  
E-mail: dspence@robarts.ca Phone 519-663-3113; fax 519-663-3018

#### REFERENCES

1. Singh G, Miller JD, Huse DM, Pettit D, D'Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. *J Rheumatol* 2003;30:714-9.
2. Wong DG, Spence JD, Lamki L, Freeman D, McDonald JWD. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. *Lancet* 1986;1:997-1001.

### Acute Polyarthritis Related to Once-Weekly Alendronate in a Woman with Osteoporosis

To the Editor:

In regard to reports of alendronate therapy<sup>1</sup>, we describe our experience treating a woman for postmenopausal osteoporosis with a once-weekly formulation of bisphosphonate, who, 12 hours after each intake, developed severe myalgia and symmetrical polyarthritis. She recovered spontaneously without sequelae.

A 63-year-old woman had a history of total hysterectomy at the age of 42 years and of recurrent episodes of lumbar pain since the age of 60. She also had pains involving the base of both thumbs and the right big toe, related to osteoarthritis (OA). Lumbar radiographs showed mild signs of OA of the zygapophyseal joints of the last 2 lumbar vertebrae. Densitometry dual energy x-ray absorptiometry evaluation revealed reduced mineral density in both vertebral (T score -3.6) and femoral neck (T score -2.02) sites. Postmenopausal osteoporosis was diagnosed.

For therapy, she was given once-weekly alendronate (70 mg) in addition to oral calcium (1 g daily) and vitamin D3 (800 IU daily). Twelve hours after the first ingestion of alendronate, she started to have severe diffuse myalgia and pains of both hands, feet, and knee joints; the pain was so severe that she was confined to her bed for one day. There was no fever, chills, cutaneous erythema, or esophageal irritation. After the second dose of alendronate 70 mg, one week later, she experienced the same symptoms. Clinical examination after 3 days revealed swelling of both wrists, index fingers (Figure 1), forefeet, and the right knee. Flexion of the fingers was limited bilaterally. The grip strength was very weak. Aspiration of the right knee yielded 4 ml of synovial fluid, which contained 6800 leukocytes/mm<sup>3</sup> (30% polymorphonuclears, no eosinophils); no birefringent crystals were seen. C-reactive protein (CRP) was 14 mg/l. Erythrocyte sedimentation rate (ESR; Westergren) was 16 mm/h. Rheumatoid factor was negative. Radiographs of the hands and knee joints revealed mild signs of OA. There was no chondrocalcinosis. Sacroiliac joints were normal on pelvic radiographs. Alendronate was discontinued. During the 6 month followup






Figure 1. Swelling of both wrists and index fingers in our patient.

myalgia and symptoms of arthritis did not reappear. CRP values returned to normal (3 mg/l) after 10 days. ESR after one month was 6 mm/h.

To our knowledge, this is the first report of acute polyarthritis that can be related to therapy with alendronate. In a series of 476 patients receiving glucocorticoids treated with oral daily alendronate, no case of arthritis as an adverse event was reported<sup>2</sup>. In a series of 38 children treated with daily alendronate during 1 year, one dropped out of the study after the first 2 days of therapy because of severe bone pain<sup>3</sup>. With pamidronate given intravenously to patients with osteoporosis or conditions related to cancer, Thiébaud, *et al*<sup>4</sup> have reported bone pains, arthralgia, and flu-like syndrome in 12.5%. These authors postulated that this reaction, which resembled the acute phase response, could be mediated by release of cytokines after bisphosphonate therapy. In an *in vitro* study, the same authors<sup>3</sup> found an increase of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin 6 (IL-6) in blood incubated with 2 aminobisphosphonates, pamidronate and zoledronate. In a collagen-induced arthritis model in mice, the aminobisphosphonates showed an exacerbating effect on development of the arthritis<sup>5</sup>. Alendronate, also an aminobisphosphonate, has been found to favor cytokine release by macrophages (IL-1 $\beta$ , IL-6, and TNF- $\alpha$ ); however, this effect was not observed with a non-nitrogen-containing bisphosphonate, clodronate<sup>6</sup>. These findings suggested to the authors that amino-containing bisphosphonates such as alendronate could have proinflammatory properties<sup>6</sup>. However, in chronic inflammatory arthritides, the effect of longterm treatment with bisphosphonates is still controversial<sup>7</sup>.

Our observation suggests that not only arthralgia but also transient true polyarthritis may be a rare side effect of alendronate given to patients with primary osteoporosis. Whether this compound could also occasionally aggravate articular manifestations in patients with preexisting chronic arthritis such as rheumatoid arthritis should be assessed in prospective studies.

JEAN C. GERSTER, MD, Professor of Rheumatology, Division of Rheumatology, Centre Hospitalier Universitaire Vaudois, Av. Pierre Decker 5, CH 1011 Lausanne; FRANÇOIS NICOLE, MD, General Practitioner, Lausanne, Switzerland.  
E-mail: jean-charles.gerster@chuv.hospvd.ch

## REFERENCES

1. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. *Alendronate Once-Weekly Study Group*. *Aging* 2000;12:1-12.
2. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. *Arthritis Rheum* 2000;44:202-11.

3. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. *Arthritis Rheum* 2000;43:1960-6.
4. Thiébaud D, Sauty A, Burckhardt P, et al. An *in vitro* and *in vivo* study of cytokines in the acute-phase response associated with bisphosphonates. *Calcif Tissue Int* 1997;61:386-92.
5. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. *Br J Pharmacol* 1996;119:205-12.
6. Makkonen N, Salminen A, Rogers JM, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. *Eur J Pharm Sci* 1999;8:109-18.
7. Maksymowych P. Bisphosphonates for arthritis — a confusing rationale. *J Rheumatol* 2003;30:430-4.

## Wegener's Granulomatosis with Massive Skin Necrosis

To the Editor:

Wegener's granulomatosis (WG) is an idiopathic multisystem necrotizing vasculitis of small and medium size vessels with a predilection for the upper airways, lungs, and kidneys<sup>1,2</sup>. Skin manifestations of WG occur in 17% to 50% of patients<sup>2</sup>, and include pustules, maculae, bullae, palpable purpura, and petechiae, mainly on the lower (52%) and upper (22%) extremities<sup>1,3</sup>. Most skin biopsies in WG show nonspecific histopathology; in only 25% of cases can typical features such as leukocytoclastic vasculitis (80%) or extravascular granuloma (10%) be found<sup>1,3</sup>. We describe a case of WG with a diffuse cutaneous necrosis.

A 38-year-old man was referred to our university hospital because of extensive cutaneous necrosis (roughly 14% of the total body surface area), associated with fever and dyspnea. He had been well until 3 months earlier, when he noted a slight edema of the left eyelid and exophthalmus, along with arthralgias. A month later he presented with fever, nonproductive cough, hemoptysis, a bloody nasal discharge, and maculonodular hemorrhagic rash followed by rapid necrosis (Figure 1A). Laboratory abnormalities included elevated inflammation markers, anemia (hemoglobin 9 g/dl), leukocytosis (18,000/mm<sup>3</sup>), proteinuria (< 7 g/day), microhematuria, and elevated serum creatinine (229.7  $\mu$ mol/l) and liver enzymes.

Immunological tests revealed the presence of antineutrophil cytoplasmic antibodies (c-ANCA) at a titer of 1:40, identified as antiproteinase-3 antibodies by ELISA. Antinuclear, anticardiolipin, and anti- $\beta_2$  glycoprotein I antibodies, along with tests for lupus anticoagulant and cryoglobulins, were negative. Factor V Leiden was absent; protein C and S concentrations were normal. Hepatitis B and C viruses and human immunodeficiency virus tests were negative. Cultures of bronchoalveolar lavage were negative, as were blood cultures. Chest radiograph showed a nodular infiltrate (4  $\times$  3 cm) in the right upper lobe, confirmed by computer tomography (CT) scan. CT scan of the facial region revealed a mucous membrane thickening in both maxillary sinuses and a hyperdensity in the left orbit, with no bone or muscle infiltration.

A diagnosis of WG was established. He was successfully treated with intravenous methylprednisolone (1 mg/kg daily) and IV pulses of cyclophosphamide (1000 mg) every fourth week along with 3 broad-spectrum antibiotics. Topical treatment of skin lesions included ethacridine lactate, 10% NaCl, followed by gradual excisions of necrotic tissue. In the following weeks his condition improved, with a complete healing of necrotic changes at 6 months (Figure 1B) and resolution of the consolidation in the right lung.

To our knowledge, this is the first report on a massive skin necrosis in a patient with WG. Necrotizing ulcerations or digital necrosis are rare manifestations of WG<sup>3,4</sup>; their surface is much smaller than in our patient<sup>1,3,5</sup>. Skin lesions indicate active systemic disease, especially with renal involve-



Figure 1. Cutaneous necrosis on the lower extremities on admission (A), which healed after 6-month treatment with scarring and slight discoloration (B).

ment<sup>6</sup>. Differential diagnosis included other autoimmune diseases with common skin manifestations: polyarteritis nodosa, microscopic polyangiitis, cutaneous leukocytoclastic vasculitis, giant cell arteritis, and angiocentric lymphomas, along with diseases referred to as ANCA-associated vasculitis (microscopic polyangiitis, Churg-Strauss vasculitis, necrotizing pauci-immune glomerulonephritis)<sup>7</sup>. Our patient fulfilled clinical and laboratory criteria for the diagnosis of WG, supported by a good response to cyclophosphamide<sup>8</sup>. Further, absence of the necrotic core and violaceous border speak against pyoderma gangrenosum. The patient did not receive coumarins, a potential cause of skin necrosis.

Since he presented with extensive necrosis, a skin biopsy was not performed for ethical reasons (risk of provoking new ulcers at the biopsy site<sup>4</sup>). In this case, rapid initiation of aggressive immunosuppression and wound care led to therapeutic success.

Our case illustrates that skin necrosis, although rare, could be a potentially devastating manifestation of WG that requires a rapid diagnosis and vigorous treatment.

AGNIESZKA CYBULSKA, MD; ANETTA UNDAS, MD, PhD;  
WOJCIECH J. SYDOR, MD; AGNIESZKA FLAK, MD; JACEK  
MUSIAL, MD, PhD, Department of Medicine, Jagiellonian University  
School of Medicine, Skawinska 8, PL-31-066 Kraków; ANTONI  
SYDOR, MD, PhD, Department of Internal Medicine, Nephrology and  
Center of Dialysis, Saint Lucas Hospital, Tarnów, Poland.

#### REFERENCES

1. Daoud MS, Gibson LE, DeRemee RA, Specks U, el-Azhary RA, Su WP. Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of 30 patients. *J Am Acad Dermatol* 1994;31:605-12.

2. Barksdale SK, Hallahan CW, Kerr GS, Fauci AS, Stern JB, Travis WD. Cutaneous pathology in Wegener's granulomatosis: A clinicopathologic study of 75 biopsies in 46 patients. *Am J Surg Pathol* 1995;19:161-72.
3. Patten SF, Tomecki KJ. Wegener's granulomatosis: cutaneous and oral mucosal disease. *J Am Acad Dermatol* 1993;28:710-8.
4. Walsh JS, Gross DJ. Wegener's granulomatosis involving the skin. *Cutis* 1999;64:183-6.
5. Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener's granulomatosis: Survey of 701 patients in North America. Changes in outcome in the 1990s. *J Rheumatol* 2002;29:309-16.
6. Frances C, Du LT, Piette JC, et al. Wegener's granulomatosis. Dermatological manifestations in 75 cases with clinicopathologic correlation. *Arch Dermatol* 1994;130:861-7.
7. Gibson LE, Su WP. Cutaneous vasculitis. *Rheum Dis Clin North Am* 1995;21:1097-113.
8. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990;33:1101-7.

#### Juvenile Polyarteritis: Is It a Different Disease?

To the Editor:

In 1897, Still suggested that the rheumatoid arthritis of children was different than that of adults<sup>1</sup>. He contended that the disease in children started in childhood and had an insidious onset. He also pointed out the marked differences in clinical features and sex distribution, and suggested it might

include more than one disease<sup>1</sup>. Today, juvenile (idiopathic) arthritis is still evolving in terms of nomenclature and classification.

Küssmaul and Maier had described polyarteritis nodosa (PAN) some 30 years before Dr. Still's report<sup>2</sup>. The description was based on pathology, where necrotizing arteritis characterized the disease. In 1994, PAN was separated into 2 subtypes according to the vessel size involvement, on the basis of the classical presentations in adults: classic PAN and microscopic polyangiitis<sup>3</sup>.

The peak frequency of PAN in adults is in ages 40s and 50s, whereas in children the peak age of onset is before puberty, around 10 years<sup>4,10</sup>. Both classic PAN and microscopic polyangiitis in adults are known to be more common in males; however, in children the frequency is roughly equal<sup>5,8,9</sup>. In adults the disease has a poor outcome. In children, however, the outcome is better<sup>6,9,10</sup>. In adults the reported survival rates are around 80%. On the other hand mortality is very rare in children after the 1990s; indeed there were no deaths reported in the 2 recent series published after 1997<sup>9,10</sup>. The disease in children has a rather insidious onset as in juvenile idiopathic arthritis.

Clinical features of the disease in children are also different than in adults. The pulmonary-renal involvement that characterizes microscopic polyangiitis is very rare in children; the typical cases with high myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) have been rarely reported<sup>9,11</sup>. In adults there are large series of reports with classic PAN associated with hepatitis B surface antigen (HBsAg)<sup>12</sup>. This group is very rare in children, which may partially be due to the increased vaccination in children. Although we had described a number of patients associated with HBsAg in our series before 1990, we have seen only 2 cases since 1990<sup>7</sup>. However, when present it necessitates a different treatment regimen.

Thus the typical presentation in children is of isolated one or 2 organ involvement, with constitutional symptoms, and the diagnosis is often based on pathology. Further, the disease does not necessarily confine itself according to vessel size<sup>13</sup>.

As well, a large group of child patients are characterized by cutaneous PAN, which is rare in adults and is not even included in the Chapel Hill nomenclature criteria<sup>5,5</sup>. Thus, similarly to juvenile arthritis, we may talk about subtypes in childhood PAN. These may be: (1) Cutaneous PAN: this will be disease confined to the skin. These patients may describe accompanying myalgia, arthralgia, and sometimes arthritis. (2) Systemic PAN with organ involvement other than the skin, regardless of the vessel size (both small and middle size). Constitutional symptoms and elevated acute phase reactants are almost always present. (3) Microscopic polyarteritis as in adults associated with MPO-ANCA: this would be the typical pulmonary-renal syndrome with a guarded prognosis. Some patients may just present with renal disease (pauci-immune, crescentic necrotizing glomerulonephritis) or, rarely, just pulmonary disease. (4) Hepatitis B associated classic PAN of adults: this is an immune complex disease characterized by aneurysms in the renal arteries.

These 4 groups have different etiology; cutaneous PAN is associated with streptococci, whereas the last group is associated with HBsAg<sup>13,14</sup>. They have different disease courses<sup>5,6,13</sup>. They also require different treatment regimens, which remain to be proven<sup>15</sup>. As pediatricians, we need to validate our own classification criteria and severity scores, and to develop treatment protocols for the disease subtypes. These subtypes may well be different parts of the spectrum of the same disease process, which vary in their manifestations according to the modifier genes/factors. In the future we may be able to define these factors; for the time being the features noted here may justify a subclassification.

Infantile PAN has not been included as a separate subtype, since probably all the cases reported in the literature fit with the classification of Kawasaki's disease<sup>16</sup>.

Since the disease has different features and perhaps different subtypes, it might be time that we recognize PAN in children as a different entity, and call it "juvenile PAN."

SEZA OZEN, MD, Professor, Department of Pediatrics, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.  
E-mail: sezaozen@hacettepe.edu.tr

*The author would like to thank Dr. David N. Glass for reviewing this manuscript.*

## REFERENCES

1. Still GF. On a form of chronic joint disease in children. *Med Chir Trans* 1897;80:47.
2. Kussmaul A, Maier K. Über eine bisher nicht beschriebene Eigenthümliche Arterinerkrankung (Periarteritis nodosa). *Dsch Arch Klin Med* 1866;1:484.
3. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. *Arthritis Rheum* 1994;37:187-92.
4. Adu D, Bacon PA. Classical PAN, microscopic polyarteritis and Churg Strauss syndrome. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. *Oxford textbook of rheumatology*. Oxford: Oxford University Press; 1998:1351-65.
5. Cassidy J, Petty RE. PAN and related vasculitides. In: Cassidy JT, Petty RE, editors. *Textbook of pediatric rheumatology*. 4th ed. Philadelphia: W.B Saunders Co.; 2001:595-603.
6. Dillon M. Primary vasculitis in children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. *Oxford textbook of rheumatology*. Oxford: Oxford University Press; 1998:1402-12.
7. Ozen S, Besbas N, Saatci U, Bakkaloglu A. Diagnostic criteria for polyarteritis nodosa in childhood. *J Pediatr* 1992;2:206-9.
8. Fink CW. Polyarteritis and other diseases with necrotizing vasculitis in childhood. *Arthritis Rheum* 1997;20:378-84.
9. Bakkaloglu A, Ozen S, Baskin E, et al. The significance of ANCA in microscopic polyangiitis and classic polyarteritis nodosa. *Arch Dis Child* 2001;85:427-30.
10. Maeda M, Kobayashi M, Okamoto S, et al. Clinical observation of 14 cases of childhood PAN in Japan. *Acta Paediatr Jpn* 1997;39:277-9.
11. Ellis EN, Wood EG, Berry P. Spectrum of disease associated with ANCA in pediatric patients. *J Pediatr* 1995;126:40-3.
12. Guillevin L, Lhote F, Amoroux J, et al. ANCA, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg Strauss syndrome. *Br J Rheumatol* 1996;35:958-64.
13. Ozen S. The spectrum of vasculitis in children. *Ballieres Best Pract Res Clin Rheumatol* 2002;16:411-25.
14. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. *Arch Dis Child* 1993;69:685-8.
15. Yalcindag A, Sundel R. Vasculitis in childhood. *Curr Opin Rheumatol* 2001;13:422-7.
16. Landing BH, Larson EJ. Are infantile PA with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? *Pediatrics* 1977;59:651-62.

---

## Book Review

### Targeted Therapies in Rheumatology

Josef S. Smolen and Peter E. Lipsky, Editors, New York, USA, London, UK: Martin Dunitz, 2003, 729 pages, price: \$130.00 US.

This comprehensive text focuses on newly emerging pathophysiologic targets and novel emerging targeted therapies for rheumatic diseases. It comprises 8 sections and 43 chapters covering reviews of basic science and clinical relevance of these topics.

In Section I, the roles of all cell types, including T and B cells, dendritic cells, mast cells, macrophages and fibroblast-like synoviocytes and cell surface receptors with their inherent pathways relevant to rheumatic disorders are reviewed. What is known of pathogenetic and pharmacologic concepts from the known basic science is discussed.

In addition to chapters on the roles of chemokines and cytokines such as tumor necrosis factor- $\alpha$ , the pertinent interleukins, and osteoprotegerin, Section II reviews their effector molecules and the roles they play in the immune response of rheumatic diseases. Their functions are analyzed in terms of the Th1/Th2 and pro-/anti-inflammatory balance in both experimental models and human disease. Using both models, Section III goes on to explore the physiology and roles for the transcription factors nuclear factor- $\kappa$ B, STATs, and JAKs (Janus kinase and signal transducer and activator of transcription), the signaling factors inducible nitric oxide synthase, cyclooxygenase, inhibitors of complement, and matrix metalloproteinases.

In Section IV, the knowledge of the response to biotherapeutics is explored in a spectrum of rheumatic disease including rheumatoid arthritis, early rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, and vasculitis. Additional chapters are devoted to ethical issues in rheumatologic investigation and practice, randomized controlled trials, longterm observational controlled trials, and regulatory issues.

This work is of sufficient scope to be recommended for those wanting a review of the basic science behind biotherapeutics, for translational researchers bringing targeted therapies to human rheumatic diseases, and for interested clinicians using them in practice.

Vivian P. Bykerk, BSc (Hons), MD, FRCPC, Assistant Professor of Medicine, University of Toronto, Consultant, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5

## Correction

Kötter I, Stübiger N. Therapeutic implications for interferon- $\alpha$  in arthritis [letter]. *J Rheumatol* 2004;31:624-5. Fish EN [reply]. The second paragraph, fourth sentence of Dr. Fish's reply should read: "It is the very nature of IFN-alphas as pleiotropic biological response modifiers that suggests their therapeutic potential: their ability to target different cell populations, thereby affecting cellular communication and immunological control at multiple levels." We regret the error.